Insider grant at Nuvectis Pharma (NVCT) adds 150,000 restricted shares

Rhea-AI Filing Summary

Nuvectis Pharma, Inc. reported that Chief Dev. & Ops. Officer Shay Shemesh received an award of 150,000 shares of restricted common stock on 01/06/2026 at a price of $0 per share.

The restricted shares will vest in equal annual installments over three years beginning on the first anniversary of the grant date, subject to his continued service. After this grant, Shemesh beneficially owns 1,793,068 shares of Nuvectis common stock, including restricted shares, held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shemesh Shay

(Last) (First) (Middle)

C/O NUVECTIS PHARMA, INC.

1 BRIDGE PLAZA, SUITE 275

(Street)

FORT LEE NJ 07024

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuvectis Pharma, Inc. [ NVCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Dev. & Ops. Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		A		150,000(1)	A	$0	1,793,068(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The 150,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Shemesh's continued service on such dates.

2. Includes shares of restricted common stock.

	/s/ Shay Shemesh	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did NVCT report in this Form 4?

Nuvectis Pharma, Inc. reported that Chief Dev. & Ops. Officer Shay Shemesh received an award of 150,000 shares of restricted common stock on 01/06/2026 at a price of $0 per share.

How many Nuvectis Pharma (NVCT) shares does Shay Shemesh own after this grant?

Following the reported restricted stock grant, Shay Shemesh beneficially owns 1,793,068 shares of Nuvectis Pharma common stock, held directly, including restricted shares.

What is the vesting schedule for Shay Shemesh’s 150,000 restricted NVCT shares?

The 150,000 shares of restricted common stock will vest in equal annual installments over three years, beginning on the first anniversary of the grant date, subject to Mr. Shemesh’s continued service on those dates.

What role does the reporting person hold at Nuvectis Pharma (NVCT)?

The reporting person, Shay Shemesh, serves as Chief Development & Operations Officer of Nuvectis Pharma, Inc., and filed this Form 4 as an officer.

Is the reported Nuvectis Pharma (NVCT) transaction a direct or indirect holding?

The Form 4 shows the shares as held directly (D) by Shay Shemesh, with no separate entity indicated in the nature of ownership field.